Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov 7;16(1):304.
doi: 10.1186/s12967-018-1678-1.

Is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail

Affiliations
Review

Is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail

Pandora Pound et al. J Transl Med. .

Abstract

Background: The pharmaceutical industry is in the midst of a productivity crisis and rates of translation from bench to bedside are dismal. Patients are being let down by the current system of drug discovery; of the several 1000 diseases that affect humans, only a minority have any approved treatments and many of these cause adverse reactions in humans. A predominant reason for the poor rate of translation from bench to bedside is generally held to be the failure of preclinical animal models to predict clinical efficacy and safety. Attempts to explain this failure have focused on problems of internal validity in preclinical animal studies (e.g. poor study design, lack of measures to control bias). However there has been less discussion of another key factor that influences translation, namely the external validity of preclinical animal models.

Review of problems of external validity: External validity is the extent to which research findings derived in one setting, population or species can be reliably applied to other settings, populations and species. This paper argues that the reliable translation of findings from animals to humans will only occur if preclinical animal studies are both internally and externally valid. We review several key aspects that impact external validity in preclinical animal research, including unrepresentative animal samples, the inability of animal models to mimic the complexity of human conditions, the poor applicability of animal models to clinical settings and animal-human species differences. We suggest that while some problems of external validity can be overcome by improving animal models, the problem of species differences can never be overcome and will always undermine external validity and the reliable translation of preclinical findings to humans.

Conclusion: We conclude that preclinical animal models can never be fully valid due to the uncertainties introduced by species differences. We suggest that even if the next several decades were spent improving the internal and external validity of animal models, the clinical relevance of those models would, in the end, only improve to some extent. This is because species differences would continue to make extrapolation from animals to humans unreliable. We suggest that to improve clinical translation and ultimately benefit patients, research should focus instead on human-relevant research methods and technologies.

Keywords: External validity; Human-relevant methods; Preclinical animal models; Translation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The relationship between internal validity, external validity and translation

Similar articles

Cited by

References

    1. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov. 2010;9(3):203. doi: 10.1038/nrd3078. - DOI - PubMed
    1. Loscalzo J. Personalized cardiovascular medicine and drug development: time for a new paradigm. Circulation. 2012;125(4):638–645. doi: 10.1161/CIRCULATIONAHA.111.089243. - DOI - PMC - PubMed
    1. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32(1):40. doi: 10.1038/nbt.2786. - DOI - PubMed
    1. Innovate UK. A non-animal technologies roadmap for the UK: advancing predictive biology. 2015. https://assets.publishing.service.gov.uk/government/uploads/system/uploa.... Accessed 22 May 2018.
    1. Deloitte. A new future for R&D? Measuring the return from pharmaceutical innovation 2017. 2017. https://www2.deloitte.com/content/dam/Deloitte/uk/Documents/life-science.... Accessed 10 July 2018.